NCT03956303

Brief Summary

The investigator's aim is to compare the efficacy of 3 levobupivacaine solutions with different density on spinal anesthesia for caesarean delivery.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jun 2014

Typical duration for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2014

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2016

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

May 14, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 20, 2019

Completed
Last Updated

May 20, 2019

Status Verified

May 1, 2019

Enrollment Period

2 years

First QC Date

May 14, 2019

Last Update Submit

May 17, 2019

Conditions

Keywords

Anesthesia, SpinalCesarean SectionLevobupivacaine

Outcome Measures

Primary Outcomes (7)

  • Change of time to reach T10 sensory spinal block level at intraoperative period by pinprick test

    time to reach T10 sensory block by pinprick test

    Every 3 minutes for 15 minutes and every 5 minutes afterwards up to 60 minutes after induction of spinal anesthesia.In these evaluation periods, the sensory block will be recorded when the T10 is detected.

  • Spinal Block Quality by questioning

    the intensity of spinal block will be evaluated via questioning the surgeon and the patient. the surgeon will grade the abdominal relaxivity as good, medium or poor The patient will evaluate spinal block analgesia quality as good, medium or poor.

    At the end of surgery

  • Change the sensory block level at intraoperative period by pinprick test

    the level of maximum sensory block by pinprick test

    Every 3 minutes for 15 minutes and every 5 minutes afterwards up to 60 minutes after induction of spinal anesthesia. The highest measured level by pinprick test be recorded

  • time to reach maximum level of sensory block at intraoperative period by pinprick test

    time to reach maximum level of sensory block by pinprick test

    Every 3 minutes for 15 minutes and every 5 minutes afterwards up to 60 minutes after induction of spinal anesthesia. the time to reach the highest measured by pinprick test will be recorded.

  • Change over time at the level of sensory block at intraoperative period by pinprick test

    time to two segment regression of maximum sensory block by pinprick test

    Every 3 minutes for 15 minutes and every 5 minutes afterwards up to 60 minutes after induction of spinal anesthesia. The time to two segment regression of maximum sensory block by pinprick test will be recorded.

  • Change in motor block level from PACU to discharge

    motor block recovery time by bromage scale

    every 15 minutes until end of surgery and 30 minutes postoperatively up to 2 hours by Bromage Scale

  • Change to regression of sensory block by pinprick test

    time to S2 regression of sensory block by pinprick test

    In the postoperative period, changes in sensory block level will be recorded at 30 min intervals up to 2 hours

Secondary Outcomes (3)

  • Haemodynamic evaluation by mmHg for systolic , diastolic and mean arterial blood pressure

    Every 3 minutes for 15 minutes and every 5 minutes afterwards up to 60 minutes after induction of spinal anesthesia. every 30 minutes up to 2 hours

  • Number of participants with postoperative complications ( head ache, back pain, numbness of lower extremity )by phone

    on postoperative day 3 by phone.

  • evaluation of umbilical vein blood gas analysis

    immediately after fetus delivery

Study Arms (4)

Plain Levobupivacaine (Chirocaine (% 0.5)

ACTIVE COMPARATOR

Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain

Drug: Chirocaine %0.5

Levobupivacaine (Chirocaine % 0,75) + dextrose 40

ACTIVE COMPARATOR

Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40

Drug: Chirocaine Heavy 40

Levobupivacaine (Chirocaine % 0,75) + dextrose 60

ACTIVE COMPARATOR

Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60

Drug: Chirocaine Heavy 60

Levobupivacaine (Chirocaine % 0,75) + dextrose 80

ACTIVE COMPARATOR

Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80

Drug: Chirocaine Heavy 80

Interventions

Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl

Also known as: Plain levobupivacaine, Group 1
Plain Levobupivacaine (Chirocaine (% 0.5)

Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl

Also known as: levobupivacaine heavy 40, Group 2
Levobupivacaine (Chirocaine % 0,75) + dextrose 40

Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl

Also known as: levobupivacaine heavy 60, Group 3
Levobupivacaine (Chirocaine % 0,75) + dextrose 60

Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl

Also known as: levobupivacaine heavy 80, Group 4
Levobupivacaine (Chirocaine % 0,75) + dextrose 80

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ASA I-II
  • Pregnancy at Term
  • Scheduled for elective caesarean delivery

You may not qualify if:

  • contraindication for spinal anesthesia
  • drug allergy
  • pregnancy related disorders (hypertension, placenta previa, fetal problems)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Ozlem Sagir, Assist. Prof

    Balikesir University School of Medicine Department of Anesthesia and Reanimation

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associated Professor

Study Record Dates

First Submitted

May 14, 2019

First Posted

May 20, 2019

Study Start

June 1, 2014

Primary Completion

June 1, 2016

Study Completion

August 1, 2016

Last Updated

May 20, 2019

Record last verified: 2019-05